Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00193492 · ClinicalTrials.gov registry record · Phase 2

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

A Phase 2 study of Lymphoma, Follicular, sponsored by SCRI Development Innovations.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
20
Study locations

NCT00193492 is a Phase 2 study of Lymphoma, Follicular that has completed, run by SCRI Development Innovations. The registered enrollment target is 60 participants, below the 125-participant average among 9 other Lymphoma, Follicular trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00193492, a Phase 2 study of Lymphoma, Follicular, has completed, sponsored by SCRI Development Innovations.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the feasibility, efficacy and safety of adding bevacizumab to rituximab compared to rituximab alone in patients with previously treated follicular non-hodgkin's lymphoma (NHL) whose disease has progressed following at least one previous chemotherapy regimen and not more than 2 previous chemotherapy regimens.

Conditions Studied

Lymphoma, Follicular

Interventions

  • DRUG Bevacizumab
  • DRUG Rituximab

Study Locations (20)

Florida

  • Florida Cancer Specialists - Fort Myers
  • Integrated Community Oncology Network - Jacksonville
  • Watson Clinic for Cancer Research - Lakeland
  • Florida Hospital Cancer Institute - Orlando

Georgia

  • Medical Oncology Associates of Augusta - Augusta
  • Northeast Georgia Medical Center - Gainesville
  • Wellstar Cancer Research - Marietta

Kentucky

  • Graves-Gilbert Clinic - Bowling Green
  • Baptist Hospital East - Louisville
  • Norton Cancer Institute - Louisville

Maryland

  • Center for Cancer and Blood Disorders - Bethesda
  • National Capital Clinical Research Consortium - Bethesda

Arkansas

  • Northeast Arkansas Clinic - Jonesboro

Indiana

  • Providence Medical Group - Terre Haute

Louisiana

  • Hematology Oncology Clinic, LLP - Baton Rouge

Nebraska

  • Methodist Cancer Center - Omaha

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2005-09
Est. Completion 2013-03
Phase Phase 2

Sponsor

SCRI Development Innovations

146 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00193492

The ClinicalTrials.gov registry entry for NCT00193492 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 9 other Lymphoma, Follicular trials with a reported enrollment target (52% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma, Follicular appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.

NCT00193492 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Georgia, Kentucky.

Frequently Asked Questions

What is clinical trial NCT00193492 about?

NCT00193492 is a clinical study titled "A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma". The purpose of this study is to assess the feasibility, efficacy and safety of adding bevacizumab to rituximab compared to rituximab alone in patients with previously treated follicular non-hodgkin's lymphoma (NHL) whose disease has progressed following at least one previous chemotherapy regimen and...

What is the current status of trial NCT00193492?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2005-09. Estimated completion is 2013-03.

What conditions does trial NCT00193492 study?

This clinical trial studies the following conditions: Lymphoma, Follicular.

What interventions are being tested in trial NCT00193492?

The interventions under investigation include: Bevacizumab (DRUG), Rituximab (DRUG).

Who is sponsoring clinical trial NCT00193492?

This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00193492 being conducted?

This trial has 20 study locations across Arkansas, Florida, Georgia, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma, Follicular

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma, Follicular

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.